Abstracts tagged "Anti-TNF therapy and rheumatoid arthritis (RA)"

Abstract Number: 486 • 2015 ACR/ARHP Annual Meeting
Persistence Among Rheumatoid Arthritis Patients Initiating Intravenous or Subcutaneous Anti-Tumor Necrosis Factor Therapy in a Large US Registry Cohort
Dennis Parenti¹, Shelly Kafka¹, George W. Reed², Jeffrey D. Greenberg^2,3 and Raphael DeHoratius^1,4, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Corrona, LLC, Southborough, MA, ³NYU School of Medicine, New York, NY, ⁴Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: The objective of this analysis was to examine persistence with intravenous (IV) and subcutaneous (SC) anti-TNF therapies among rheumatoid arthritis (RA) patients (pts) within…
Abstract Number: 572 • 2015 ACR/ARHP Annual Meeting
Predictors of Long-Term Retention of Infliximab and Golimumab in Rheumatoid Arthritis: An Analysis from a Prospective, Observational Registry
Edward C. Keystone¹, Philip Baer², Mary J. Bell³, Andrew Chow⁴, Louis Bessette⁵, Boulos Haraoui⁶, Wojciech Olszynski⁷, John Kelsall⁸, Emmanouil Rampakakis⁹, John S. Sampalis⁹, Allen J Lehman¹⁰, Francois Nantel¹¹, Brendan Osborne¹², Cathy Tkaczyk¹² and Karina Maslova¹⁰, ¹University of Toronto/Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Toronto, ON, Canada, ²Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, ³Rheum Div, Sunnybrook Health Sciences Centre/University of Toronto, Toronto, ON, Canada, ⁴University of Toronto/McMaster University, Mississauga, ON, Canada, ⁵Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ⁶Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have shown differences in treatment retention between anti-TNF agents. Furthermore, although inconsistent, data from the literature suggest that some factors (e.g. concomitant…
Abstract Number: 1292 • 2015 ACR/ARHP Annual Meeting
What Is the Effect of TNF Inhibitors on Employment Status in Rheumatoid Arthritis Patients and What Are the Predictors of Progression to Unemployment?
Andrew Chow¹, Regan Arendse², Wojciech Olszynski², John Kelsall³, Milton F. Baker⁴, William G Bensen⁵, Philip Baer⁶, Anna Jaroszynska⁷, Denis Choquette⁸, Suneil Kapur⁹, Jacqueline Stewart¹⁰, Emmanouil Rampakakis^11,12, Eliofotisti Psaradellis¹², Francois Nantel¹³, Susan Otawa¹⁴, Cathy Tkaczyk¹⁴, Allen J Lehman¹⁴ and Karina Maslova¹³, ¹University of Toronto/McMaster University, Mississauga, ON, Canada, ²University of Saskatchewan, Saskatoon, SK, Canada, ³Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁴VIHA, Victoria, BC, Canada, ⁵St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁶Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, ⁷Private Practice, Burlington, ON, Canada, ⁸Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁹Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹⁰Penticton Regional Hospital, Penticton, BC, Canada, ¹¹JSS Medical Research, St-Laurent, QC, Canada, ¹²JSS Medical Research, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, progressive inflammatory disease which has been associated with an increased incidence of disability and unemployment over time. The…
Abstract Number: 1315 • 2015 ACR/ARHP Annual Meeting
Detecting Subtle Changes in Bone Structure Following Three-Month Anti-TNF Theraphy Using High-Resolution Peripheral Quantitative Computed Tomography
Matthew Tanaka¹, Favian Su², Min Hee Lee^3,4, Andrew J. Burghardt⁵, Thomas M. Link⁴, Jonathan D. Graf⁶, John Imboden⁷ and Xiaojuan Li⁸, ¹University of California Berkeley, Berkeley, CA, ²Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA, ³Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, South Korea, ⁴Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA, ⁵Department of Radiology & Biomedical Imaging, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, ⁶Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ⁷Rheumatology, Rheumatology, University of California San Francisco, San Francisco, CA, ⁸Radiology & Biomedical Imaging, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA
Background/Purpose: Radiographs have been traditionally used to detect bone erosions and joint space narrowing (JSN) in rheumatoid arthritis (RA), but they are not sensitive to…
Abstract Number: 2779 • 2015 ACR/ARHP Annual Meeting
Better Drug Survival of Non-TNFi Compared to TNFi Biologics after Non-TNFi Failure in RA Patients: A Single Center Experience
Konstantinos Thomas, Christos Koutsianas, Argyro Lazarini, Christina Tsalapaki, Chrisoula Hatzara, Anna Kandili, Katerina Antonatou and Dimitrios Vassilopoulos, University of Athens Medical School, Clinical Immunology and Rheumatology Unit, 2nd Department of Medicine and Laboratory, Athens, Greece
Background/Purpose: There are sparse data in the literature regarding the drug survival of TNFi vs. non-TNFi biologics in rheumatoid arthritis (RA) patients who have already…
Abstract Number: 2483 • 2014 ACR/ARHP Annual Meeting
Treatment Adjustment Strategy after Achieving Remission or Low Disease Activity in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis
Sophie Henaux¹, Thomas Barnetche², Adeline Ruyssen Witrand³, Bruno Fautrel⁴, Alain G. Cantagrel⁵ and Arnaud Constantin⁶, ¹Centre de Rhumatologie, Hopital Purpan, Toulouse, France, ²Rheumatology, Bordeaux University Hospital, Bordeaux, France, ³Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁴GRC-UPMC 08; AP-HP, Rheumatology dépt, Pitié Salpêtrière Hospital, Paris, France, ⁵Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ⁶Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France
Conflict of interest : NONE.Background/Purpose Attaining remission or at least low-disease activity (LDA) is a goal achieved in a significant proportion of rheumatoid arthritis (RA) patients…
Abstract Number: 2422 • 2014 ACR/ARHP Annual Meeting
A Tailored Approach to Reduce Dose of TNF Inhibitors Is Equally Effective, but Substantially Less Costly Than Standard Dosing in Patients with Rheumatoid Arthritis over One and Two Years: A Prospective Cohort Study
Jakub Zavada¹, Michal Uher², Katarina Sisol³, Sarka Forejtova⁴, Katerina Jarosova⁵, Liliana Sedova³, Zuzana Urbanova⁶, Olga Sleglova⁶, Jiri Vencovsky⁷ and Karel Pavelka⁸, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ³rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁴Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁵Na Slupi 4, Institute of Rheumatology, Prague, Czech Republic, ⁶Institute of Rheumatology, Prague, Czech Republic, ⁷Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁸Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: To compare effectiveness and costs of standard versus individually tailored reduced doses of TNF inhibitors (TNFi) in patients with Rheumatoid Arthritis (RA) after achieving…
Abstract Number: 2400 • 2014 ACR/ARHP Annual Meeting
Comparing a Tapering Strategy to the Standard Dosing Regimen of TNF Inhibitors in Patients with Rheumatoid Arthritis in Remission or with Low Disease Activity
Chamaida Plasencia-Rodriguez¹, G. J. Wolbink², Charlotte L. M. Krieckaert², Eva L. Kneepkens³, Samina Turk⁴, Maria Gema Bonilla⁵, Alejandro Villalba¹, Diana Peiteado¹, Laura Nuño⁶, Mike T. Nurmohamed², Theo Rispens⁷, Desiree van der Kleij⁸, Teresa Jurado⁹, Emilio Martín-Mola¹⁰, Dora Pascual-Salcedo¹¹ and Alejandro Balsa¹², ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands, ⁴Reade, Amsterdam, Netherlands, ⁵Rheumatology Unit, La Paz University Hospital, Madrid, Spain, ⁶Hospital La Paz-IdiPaz, Madrid, Spain, ⁷Sanquin Research, Amsterdam, Netherlands, ⁸Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁹Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ¹⁰Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ¹¹Immunology, La Paz University Hospital, Madrid, Spain, ¹²Rheumatology, Hospital La Paz-IdiPaz, Madrid, Spain
Background/Purpose: There is a growing interest about optimization of biological therapies but for now no strong evidence is available to support a tapering strategy in…
Abstract Number: 397 • 2014 ACR/ARHP Annual Meeting
Th9 Lymphocytes in Rheumatoid Arthritis
Rossella Talotta¹, Angela Berzi², Fabiola Atzeni¹, Donata Dell'Acqua¹, Piercarlo Sarzi-Puttini¹ and Daria Trabattoni², ¹Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ²Chair of Immunology, Department of Biomedical and Clinical Sciences “L. Sacco, Milan, Italy
Background/Purpose Th9 cells are IL-9-secreting Th lymphocytes that are involved in the immunological responses underlying parasitic infections and allergic diseases. In the case of autoimmune…
Abstract Number: 2325 • 2013 ACR/ARHP Annual Meeting
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy
Josef S. Smolen¹, Jonathan Kay², Robert Landewé³, Eric L. Matteson⁴, Norman B. Gaylis⁵, Jürgen Wollenhaupt⁶, Frederick T. Murphy⁷, Chenglong Han⁸, Timothy A. Gathany⁸, Stephen Xu⁹, Yiying Zhou¹⁰, Elizabeth C. Hsia⁹ and Mittie K. Doyle⁹, ¹Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, ³Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁶Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ⁷Altoona Ctr for Clinical Research, Duncansville, PA, ⁸Janssen Global Services, LLC., Malvern, PA, ⁹Janssen Research & Development, LLC., Spring House, PA, ¹⁰Biostatistics, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: GO-AFTER was the first multicenter, randomized, placebo (PBO)-controlled trial of the safety/efficacy of an anti-TNFα agent, GLM, in pts with active RA despite prior…
Abstract Number: 1414 • 2013 ACR/ARHP Annual Meeting
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Prior Treatment With Methotrexate
Edward Keystone¹, Mark C. Genovese², Stephen Hall³, Pedro Miranda⁴, Sang-Cheol Bae⁵, Chenglong Han⁶, Timothy A. Gathany⁶, Yiying Zhou⁷, Stephen Xu⁸ and Elizabeth C. Hsia⁸, ¹University of Toronto/Mount Sinai Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Stanford University, Palo Alto, CA, ³Cabrini Medical Centre, Melbourne, Australia, ⁴Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶Janssen Global Services, LLC., Malvern, PA, ⁷Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁸Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: The safety and efficacy of subcutaneous golimumab (GLM)+/-MTX has been evaluated through 2yrs in a phase 3 trial (GO-FORWARD) of pts with active rheumatoid…
Abstract Number: 1416 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Subcutaneous Golimumab In Chinese Patients With Active Rheumatoid Arthritis Despite MTX Therapy: Results From a Randomized, Placebo-Controlled, Phase 3 Trial
Zhanguo Li¹, Fengchun Zhang², Jonathan Kay³, Kaiyin Fei⁴, Chenglong Han⁵, Yanli Zhuang⁴, Zhong Wu⁴ and Elizabeth C. Hsia⁴, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Janssen Global Services, LLC., Malvern, PA
Background/Purpose: Assess safety and efficacy of GLM+MTX over 1yr in a multicenter, randomized, placebo (PBO)-controlled study of Chinese pts with active RA despite MTX therapy.…
Abstract Number: 1350 • 2013 ACR/ARHP Annual Meeting
Factors Influencing Selection Of Biologic Therapy and Comparative Effectiveness In Patient Reported Outcomes Among Patients With Rheumatoid Arthritis
Iris Navarro-Millan¹, Lang Chen¹, Leslie R. Harrold², Lisa Herrinton³, Liyan Liu³ and Jeffrey R. Curtis⁴, ¹Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Massachusetts Medical School, Worcester, MA, ³Division of Research, Kaiser Permanente, Oakland, CA, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Treatment of rheumatoid arthritis (RA) with biologics is increasingly common. A better understanding of factors that influence the selection of RA therapies and comparative effectiveness…
Abstract Number: 1331 • 2013 ACR/ARHP Annual Meeting
Mathematical Model To Predict The Early Responders In a Monocentric Cohort Of Patients With Rheumatoid Arthritis Treated By Anti TNF-Alpha
Camillo Giacomelli¹, Claudia Ferrari¹, Chiara Stagnaro², Rosaria Talarico³, Arianna Consensi¹, Francesca Sernissi¹, Laura Bazzichi¹ and Stefano Bombardieri¹, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, Pisa, Italy
Background/Purpose: In the last few year the introduction of biological agents has radically changed the clinical outcome of patients with Rheumatoid Arthritis (RA). However, no…
Abstract Number: 874 • 2013 ACR/ARHP Annual Meeting
Sustained and Consistent Clinical Benefit With Intravenous Golimumab Therapy In Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 1-Year Of a Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
Clifton O. Bingham III¹, Rene Westhovens², Alan M. Mendelsohn³, Lilianne Kim⁴, Kim Hung Lo⁴ and Michael E. Weinblatt⁵, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ³Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: To report on sustainability and consistency of ACR component scores with intravenous (IV) golimumab (GLM) 2mg/kg+methotrexate (MTX) through wk52 in pts with active rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].